Small molecules in the treatment of COVID-19
S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
A global picture: therapeutic perspectives for COVID-19
VP Chavda, C Kapadia, S Soni, R Prajapati… - …, 2022 - Taylor & Francis
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
Three-dimensional visualization of viral structure, entry, and replication underlying the spread of SARS-CoV-2
JW Saville, AM Berezuk, SS Srivastava… - Chemical …, 2022 - ACS Publications
The global spread of SARS-CoV-2 has proceeded at an unprecedented rate. Remarkably,
characterization of the virus using modern tools in structural biology has also progressed at …
characterization of the virus using modern tools in structural biology has also progressed at …
Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro …
COVID-19 is an ongoing pandemic caused by the SARS-CoV-2 virus with important political,
socio-economic, and public health consequences. Inhibiting replication represents an …
socio-economic, and public health consequences. Inhibiting replication represents an …
Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone
H Jiang, P Yang, J Zhang - Frontiers in chemistry, 2022 - frontiersin.org
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the
Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos …
Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos …
Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro
DSM Lewis, J Ho, S Wills, A Kawall, A Sharma… - Scientific reports, 2022 - nature.com
The most common host entry point of human adapted coronaviruses (CoV) including SARS-
CoV-2 is through the initial colonization in the nostril and mouth region which is responsible …
CoV-2 is through the initial colonization in the nostril and mouth region which is responsible …
Drug repurposing for the SARS‐CoV‐2 papain‐like protease
As the pathogen of COVID‐19, SARS‐CoV‐2 encodes two essential cysteine proteases that
process the pathogen's two large polypeptide products pp1a and pp1ab in the human cell …
process the pathogen's two large polypeptide products pp1a and pp1ab in the human cell …
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors
M Valipour - European Journal of Medicinal Chemistry, 2022 - Elsevier
The newly emerged coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) that caused the COVID-19 pandemic, is the closest relative of SARS-CoV with high …
CoV-2) that caused the COVID-19 pandemic, is the closest relative of SARS-CoV with high …
Comprehensive consensus analysis of SARS-CoV-2 drug repurposing campaigns
The current COVID-19 pandemic has elicited extensive repurposing efforts (both small and
large scale) to rapidly identify COVID-19 treatments among approved drugs. Herein, we …
large scale) to rapidly identify COVID-19 treatments among approved drugs. Herein, we …